JIANHUA LUO
Medical Practice in Wexford, PA

License number
Pennsylvania MD061392L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Wexford, PA 15090

Personal information

See more information about JIANHUA LUO at radaris.com
Name
Address
Phone
Jianhua Luo, age 63
431 Mckean Dr, Wexford, PA 15090
Jianhua Luo
115 Greenbriar Dr, Wexford, PA 15090
Jianhua Luo, age 64
221 Buchanan Pl, Pittsburgh, PA 15228
(412) 388-0819
Jianhua Luo, age 64
431 Mckean Dr, Wexford, PA 15090

Professional information

Jianhua Luo Photo 1

Methods For Diagnosing Prostate Cancer And Predicting Prostate Cancer Relapse

US Patent:
2013007, Mar 28, 2013
Filed:
Sep 14, 2012
Appl. No.:
13/619556
Inventors:
Jianhua Luo - Wexford PA, US
George Konstantine Michalopoulos - Pittsburg PA, US
Joel Byron Nelson - Pittsburgh PA, US
Chi Song - New Haven CT, US
Chien-Cheng Tseng - Pittsburgh PA, US
Yanping Yu - Wexford PA, US
International Classification:
C12Q 1/68
US Classification:
506 9
Abstract:
The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.


Jianhua Luo Photo 2

Integrin Alpha 7 Mutations In Prostate Cancer, Liver Cancer, Glioblastoma Multiforme, And Leiomyosarcoma

US Patent:
2009000, Jan 1, 2009
Filed:
Apr 30, 2008
Appl. No.:
12/112657
Inventors:
Jianhua Luo - Wexford PA, US
International Classification:
C12Q 1/68, C12Q 1/02
US Classification:
435 6, 435 29
Abstract:
Methods are provided for determining the presence of a cancer in a biological sample, such as a tissue biopsy. The methods comprise determining if integrin alpha 7 expression is decreased in the biopsy which is indicative of the presence of a cancer or likelihood of relapse of a cancer. This can be accomplished by determining if levels of integrin alpha 7 mRNA or protein are decreased as compared to a control. This also can be accomplished by determining if a mutation in the integrin alpha 7 gene is present in the biopsy.